Association of daily step count and serum testosterone among men in the United States

Francesco Del Giudice1,2 · Frank Glover3 · Federico Belladelli2,4 · Ettore De Berardinis1 · Alessandro Sciarra1 · Stefano Salciccia1 · Alex M. Kasman2 · Tony Chen2 · Michael L. Eisenberg2,5

Received: 15 August 2020 / Accepted: 9 January 2021 / Published online: 12 February 2021 © The Author(s) 2021

Abstract
Purpose To describe the association between daily activity (i.e., daily step counts and accelerometer intensity measures) and serum TT levels in a representative sample of US adults aged 18 years or older.
Methods A retrospective cohort study was carried out utilizing the NHANES (National Health and Nutrition Examination Survey) 2003–2004 cycle. Physical activity was measured with a waist-worn uniaxial accelerometer (AM-7164; ActiGraph) for up to 7 days using a standardized protocol. Using linear and multivariable logistic regression controlling for relevant social, demographic, lifestyle, and comorbidity characteristics, we assessed the association between daily step counts and TT.
Results A total of 279 subjects with a median age 46 (IQR: 33–56) were included in the analysis. 23.3% of the cohort had a low serum TT level (TT < 350 ng/dl). Compared to men who took <4000 steps per day, men who took >4000 or >8000 steps/day had a lower odd of being hypogonadal (OR 0.14, 95% CI: 0.07–0.49 and 0.08, 95%CI: 0.02–0.44, respectively). While a threshold effect was noted on average, TT increased 7 ng/dL for each additional 1000 steps taken daily (β-estimate: 0.007, 95% CI: 0.002–0.013).
Conclusions Patients with the lowest daily step counts had higher odds of being hypogonadal. The current work supports a possible association between daily steps, total testosterone, and hypogonadism for men in the US.

Keywords Male General Health · Physical activity · Steps count · Testosterone level · NHANES · Accelerometer data

Introduction
Testosterone is necessary for normal male development and function. Abnormal testosterone levels have been associated with changes in male body muscle mass and fat distribution as well as bone metabolism and energy levels [1]. Male hypogonadism comprises of both persistent-specific symptoms and biochemical evidence of testosterone deficiency [2]. Hypogonadism becomes more prevalent with age. In particular, the EMAS study reported a 0.4% per annum decrease in total testosterone (TT) and a 1.3% per annum decline in free testosterone (fT) [3]. In addition, there is a high prevalence of hypogonadism within specific populations, including patients with type 2 diabetes, metabolic syndrome, obesity, and low performance status [4, 5].

Given the association between serum testosterone and health, it is reasonable to assume that physical activity (PA) is also associated with TT [6]. PA is an important source of physical, psychological, cognitive, and social health benefit for all age groups, including the prevention of muscle-skeletal fragility events, which may ultimately lead to long-term pain,
loss of function, and higher mortality rates in the elderly [7]. This relationship is evident in prostate cancer (PCa) survivors treated with androgen deprivation therapy (ADT) who are at higher risk for muscle mass and muscular strength decrease, loss of bone density as well as increasing in body weight and fat mass [8]. However, previous studies from the National Health and Nutrition Examination Survey (NHANES) [9, 10] were unable to detect any association between overall circulating TT levels and the amount of PA as assessed by survey responses. However, self-reports of type, duration, and intensity of PA, may be affected by recall and social desirability bias as well as by individual perception of PA intensity [11, 12]. Objective measures of PA through activity monitors may provide more reliable measures. The purpose of the current study was to describe the association between daily activity (i.e., accelerometer intensity measures) and serum TT, fT, and Bioavailable T levels in a representative sample of US adults aged 18 years or older.

Materials and methods

Study population

Data from the NHANES cycle 2003–2004 were analyzed (available from: https://wwwn.cdc.gov/nchs/nhanes/2003-2004/PAXRAW_C.htm). NHANES consists of a non-institutionalized US civilians sample, using a multistage probability sampling design that considers geographical area and minority representation via a cross-sectional survey conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (available from https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx). Sample weights are generated to create nationally representative estimates for the US population and subgroups defined by age, sex, and race/ethnicity [13]. As the analysis utilized deidentified data with no direct participant contact, it is not considered to be human subjects research and consequently does not require institutional review board approval.

Demographic information (i.e., age, ethnicity, education), health behaviors (smoking, BMI) and concomitant comorbidities were also collected. The main inclusion criteria were participants who were at least 18 years or older with available serum samples in the repository and also wore an ActiGraph model 7164 accelerometer on the hip during waking hours for a 7-day period with at least 1 day of valid wear (i.e., ≥10 h/d).

Following an overnight fast, men serum samples were firstly dawned between 8:30 and 11:30 a.m. and then testosterone concentrations were determined using a competitive electrochemiluminescence immunoassay on the 2010 Elecsys autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA) with the lowest detection limit of the assay being 0.02 ng/mL. All sex steroid hormones from the present NHANES cycle were assayed at Boston Children’s Hospital (Boston, MA, USA) by laboratory technicians blinded to participant characteristics. The details for the NHANES laboratory methodology for testosterone determination are available from: https://wwwn.cdc.gov/nchs/nhanes/2003-2004/SSCHL_C.htm. fT and Bioavailable T were then separately calculated given the serum values of sex-hormone binding globulin and albumin levels in accordance with the formula described by Vermeulen et al. [14], available from http://www.issam.ch/freetesto.htm.

Men were excluded from the analysis if they were diagnosed with medical history of PCAs (as they may be treated with hormone ablation therapy), reported limitations to engaging in PA (i.e., unable to walk without an assistive device), or were missing information on testosterone/accelerometer data or on covariates of interest. Of 2922 men aged at least 18 years old at the time of the survey, 2052 had valid accelerometer data. A total of 386 of the 2052 with accelerometer data also presented with available serum TT information. Out of these, 107 (27.7%) were excluded due to missing data reaching a final sample size of 279 subjects enrolled into analysis.

Accelerometer-measured PA

PA was measured with a waist-worn uniaxial accelerometer (AM-7164; ActiGraph LLC; Ft. Walton Beach, FL) for up to 7 days using a standardized protocol [13] within the same data acquisition time frame for each NHANES participant. The signals are then filtered and digitized by converters in the device and summed over a user-specified period of time (epoch) to provide activity counts per epoch, commonly expressed as count per minute or per day (CPD). Data were initially screened for non-wear time using a previously developed algorithm for NHANES accelerometer data [13]. Days with fewer than 10 h of wear time were excluded and participants with at least 1 valid day of accelerometer data were included in the analysis.

Pax intensity assessment

The physical activity monitors used in NHANES collected objective information on the intensity and duration of common locomotion activities such as walking, and jogging defined by the “PAXINTEN” variable, which correspond to the sequential observation number in minutes as recorded by the monitor device intensity value (available from: https://wwwn.cdc.gov/nchs/nhanes/2003-2004/PAXRAW_C.htm). Each day of wear produces 1440 individual minute records up to the last minute of day 7. Pax intensity values were classified into weighted quartiles and modeled upon
TT serum levels and the available covariates information. The 25th percentile (~<155078.6 CPD) was used as the reference [13].

Multiple imputation method for daily steps count determination

Although activity count data from the 2003–2004 NHANES cycle has been publicly available, step count data from this cycle were not released because of missing data. Several research teams previously addressed this issue by utilizing a semi-parametric multiple imputation method, whereby bootstrapping and ordinary least squares regression provided accurate values for missing data [15, 16]. This imputation method uses demographic, questionnaire, laboratory and accelerometer data on participants who are not missing steps values, to predict step values for individuals who are missing daily step values. Prior literature has validated the imputation [15]. Ordinary least squares regression on newly imputed dataset was compared to those of the pre-imputation dataset, and similar estimates of linear and/or logistic regression analysis were found between both datasets.

Statistical analysis

Following the recommended guidelines from the NCHS (Centers for Disease Control and Prevention 2012a), all the analyses were performed with appropriate weights for the complex survey sampling method of NHANES data. Student’s t test and chi-squared statistic were used to assess differences among means and proportions between continuous variables and subgroups, respectively. To explore the relationship concerning step CPD or pax intensity CPD, we examined the odds of impaired TT levels (i.e., <350 ng/dl), fT (<6.5 ng/dl), and bioavailable T (<110 ng/dl) in jointly classified categories with low step counts (<4000 steps/day) and low pax intensity (lower quartile) as reference group. Linear regression was used to estimate and compare variation of serum TT concentrations across cumulative recorded steps and pax intensity measures. One-way ANOVA on ranks (Kruskal–Wallis test) was used to test the differences concerning continuous TT levels between groups categories (steps categories and pax intensity quartiles). Multivariable logistic regression was used to estimate the odds of low TT, fT, and bioavailable T for varying step and pax intensity levels. Sensitivity analyses were performed using different TT thresholds and associations with step counts. The TT threshold was chosen from established values where men are recommended to consider hormone replacement therapy by several International American/European Andrological and/or Endocrinological Societies and similar to prior analyses [10]. Locally weighted scatter-plot smoother (LOWESS) function was used to graphically depict the relationship between continuous step/pax intensity counts and TT, fT, and Bioavailable T. The analysis was adjusted for covariates selected based on previous investigation, including age, BMI, race/ethnicity (non-Hispanic white, Mexican American, non-Hispanic black), education level (less than high school, high school, greater than high school), and smoking status (current vs. never). Moreover, the model was adjusted for all comorbidity covariates known to influence both TT homeostasis (alcohol consumption, diabetes, hypercholesterolemia, hypertension, cancer) as well as participant’s motility limitation (stroke, coronary artery disease, heart failure). Data analysis was performed using SAS v.9.2 (Cary, NC, USA) with p values < 0.05 considered statistically significant.

Results

279 men had complete data regarding accelerometer, serum TT, and covariates of interest. Overall, 214 (76.7%) men had normal TT levels and 65 men had low TT levels. Men presenting with normal TT levels (i.e., >350 ng/dl; mean 581.1 ± 182 vs. 248 ± 75) were significantly younger (p = 0.045) and had a lower mean BMI (p = 0.006) compared to men with lower TT levels. No significant nor clinically relevant differences were identified with regard to other socio-demographic, or comorbidities distribution (Table 1). Participants took a mean of 8702.2 (SD: 4337.2) steps per day while the mean pax intensity value was 249,848.5 (SD: 139,941.1). TT, fT, and Bioavailable T levels were consistently different across the step categories (p = 0.012, 0.001, and 0.005, respectively) and pax intensity quartiles (p = 0.026, 0.000, and 0.146, respectively) (Table 2).

Daily step count and TT levels

When examining the association between low testosterone levels and daily step count, the odds for impaired TT was lower with increasing step count (Fig. 1). Compared to taking <4000 steps per day, men who took 4000–8000 or 8000–12,000 had a lower odd of hypogonadal TT levels (OR 0.14, 95% CI: 0.07–0.49 and 0.08, 95% CI: 0.02–0.44, respectively). While there was a threshold effect, there was a positive association with daily step count and TT levels (β-estimate: 0.007, SE: 0.004, 95% CI: 0.002–0.013). For each 1000 steps, TT levels increase by 7 ng/dl. In addition, when examining steps as a continuous variable, the odds of hypogonadism also fell with each additional step (Fig. 2). Sensitivity analyses defining hypogonadism as TT < 300 and <250 ng/dl showed similar point estimates and trend toward significance (OR<300: 0.21, 95% CI: 0.05–0.81 and 0.19, 95% CI 0.03–1.43; OR<250: 0.19, 95% CI: 0.05–0.69 and 0.16, 95% CI: 0.02–1.2, for 4000–8000
and 8000–12,000 CPD, respectively) (Fig. 2). Higher threshold categories for steps and pax intensity (i.e., >12,000) were also examined (Fig. 2). Similarly, the adjusted odd for both impaired fT and Bioavailable T was confirmed to be significantly lower as going through the steps thresholds categories (Fig. 3a, b, respectively).

Table 1 Socio-demographic and clinical characteristics of the 279 subjects enrolled from the NHANES 2003–2004 cycle according to normal vs. low total testosterone distribution (ng/dl)

| Variables                      | Total testosterone among NHANES participants | p value |
|--------------------------------|---------------------------------------------|---------|
|                                | >350 ng/dl                                  | <350 ng/dl |         |
| Sample size, n (%)             | 214 (76.7)                                  | 65 (23.3) | –       |
| Total testosterone, ng/dl      | Mean (SD)                                   | 562.6 (168.3) | 247.4 (75.3) | 0.001 |
|                                | Median (IQR)                                | 520 (426–649) | 268 (191–314) |       |
| Free testosterone, ng/dl       | Mean (SD)                                   | 25.1 (16.3) | 11.7 (7.1) | 0.004 |
|                                | Median (IQR)                                | 18.3 (11.2–29.6) | 8.5 (5.5–14–3) |       |
| Bioavailable testosterone, ng/dl| Mean (SD)                                   | 171.8 (109.4) | 82.8 (51.6) | 0.001 |
|                                | Median (IQR)                                | 128 (67–246.5) | 64.7 (30.3–95.3) |       |
| Age, years                     | Mean (SD)                                   | 44.1 (15.3) | 50.3 (16.7) | 0.045 |
|                                | Median (IQR)                                | 44 (32–53) | 54 (35–63) |       |
| Age, group class, n (%)        | 18–39                                       | 80 (37.4) | 13 (20) | 0.11 |
|                                | 40–59                                       | 69 (32.2) | 19 (29.2) |       |
|                                | 60+                                         | 65 (30.4) | 33 (50.8) |       |
| Mexican American               | 43 (20.1)                                   | 12 (18.5) |       |       |
| Race/ethnicity, n (%)          | Non-Hispanic black                          | 42 (19.6) | 10 (15.4) | 0.37 |
|                                | Non-Hispanic white                          | 129 (60.3) | 43 (66.2) |       |
| BMI                            | Mean (SD)                                   | 27.1 (4.7) | 31.3 (5.9) | 0.006 |
|                                | Median (IQR)                                | 26.5 (24.2–30.1) | 30.7 (28–35) |       |
| BMI group class, n (%)         | 18.5–25                                     | 71 (33.2) | 8 (12.3) | 0.037 |
|                                | 25–30                                       | 87 (40.7) | 20 (30.8) |       |
|                                | >30                                         | 56 (26.2) | 37 (56.9) |       |
| Education group class, n (%)   | <High school                                | 62 (29) | 19 (29.2) | 0.31 |
|                                | High school                                 | 57 (26.6) | 13 (20) |       |
|                                | >High school                                | 95 (44.4) | 33 (50.8) |       |
| Smoking status, n (%)          | Never smoker                                | 88 (41.1) | 34 (52.3) | 0.27 |
|                                | Active smoker                               | 126 (58.9) | 31 (47.7) |       |
| Comorbidities                  | Alcohol consumption, n (%)                  | ≤2 Drink/day | 99 (46.3) | 39 (60) | 0.08 |
|                                |                                            | >2 Drink/day | 115 (53.7) | 26 (40) |       |
|                                | Diabetes, n (%)                             | No | 195 (91.1) | 50 (76.9) | 0.41 |
|                                |                                            | Yes | 19 (8.9) | 15 (23.1) |       |
|                                | High cholesterol, n (%)                     | No | 193 (90.2) | 50 (76.9) | 0.16 |
|                                |                                            | Yes | 21 (9.8) | 15 (23.1) |       |
|                                | Hypertension, n (%)                         | No | 179 (83.6) | 47 (72.3) | 0.21 |
|                                |                                            | Yes | 35 (16.4) | 18 (27.7) |       |
|                                | Stroke, n (%)                               | No | 207 (96.7) | 60 (92.3) | 0.004 |
|                                |                                            | Yes | 7 (3.3) | 5 (7.7) |       |
|                                | Coronary artery disease, n (%)              | No | 205 (95.8) | 61 (93.8) | 0.57 |
|                                |                                            | Yes | 9 (4.2) | 4 (6.2) |       |
|                                | Heart failure, n (%)                        | No | 209 (97.7) | 62 (95.4) | 0.61 |
|                                |                                            | Yes | 5 (2.3) | 3 (4.6) |       |
|                                | Cancer, n (%)                               | No | 195 (91.1) | 61 (93.8) | 0.03 |
|                                |                                            | Yes | 19 (8.9) | 4 (6.2) |       |
Similar findings to the daily step-count data were confirmed when assessing the association between pax intensity and TT levels. On multivariable logistic regression, we confirmed a lower odd of hypogonadism, fT, and Bioavailable T with cumulative increase in pax intensity values per day (Supplementary Figs. 2 and 3a, b, respectively).

In the present cross-sectional survey, we observed a positive association between daily step count and TT levels. More intense and/or overall longer PA was associated with higher TT levels and a lower odds of hypogonadism, fT, and Bioavailable T. However, PA was assessed in the year prior to the survey and is susceptible to recall bias. Evidence suggests that the increase in circulating testosterone levels only occurs within a short period of time from the onset of exercise and returns to baseline thereafter [18]. Moreover, the acute exercise-induced boost in TT has been studied [18].

### Table 2: Steps and pax intensity count per day (CPT) according to normal, normal-low, and low total testosterone values within the study population

| Variables | Normal total testosterone | Normal-low total testosterone | Low total testosterone | Normal free testosterone | Low free testosterone | Normal bioavailable testosterone | Low bioavailable testosterone |
|-----------|---------------------------|-------------------------------|-----------------------|-------------------------|----------------------|-------------------------------|-------------------------------|
|           | >350 ng/dl (n = 214)      | >250 and <350 ng/dl (n = 17) | <250 ng/dl (n = 28)  | >6.5 ng/dl (n = 241)   | <6.5 ng/dl (n = 28)  | >110 ng/dl (n = 128)           | <110 ng/dl (n = 145)           |
| Steps count, (CPD) | 19 (8.9)                  | 11 (29.7)                     | 9 (32.1)              | 0.012                   | 22 (9.5)              | 13 (31.7)                      | 0.008                         |
| 4000-4000 | 84 (39.3)                 | 15 (40.5)                     | 12 (42.9)             | 0.012                   | 22 (9.5)              | 13 (31.7)                      | 0.008                         |
| >12000   | 74 (34.6)                 | 5 (13.5)                      | 4 (14.3)              | 0.026                   | 37 (9.1)              | 1 (2.8)                        | 0.000                         |
| Pax intensity, (CPD) | 2nd Quartile (n = 55)     | 15 (50.5)                     | 15 (53.6)             | 0.002                   | 37 (38)               | 1 (2.8)                        | 0.014                         |
|           | 3rd Quartile (n = 56)     | 2 (8.6)                       | 8 (28.6)              | 0.026                   | 46 (20.8)             | 1 (2.8)                        | 0.000                         |
|           | 4th Quartile (n = 40)     | 2 (8.6)                       | 8 (28.6)              | 0.026                   | 46 (20.8)             | 1 (2.8)                        | 0.000                         |

#### Discussion

In the present cross-sectional survey, we observed a positive association between daily step count and TT levels. Moreover, the interaction between various measures of PA and testosterone levels has been studied. Previous experiences have addressed this relationship relying on self-reports on PA intensity and/or overall duration. Muller et al. [17] demonstrated that greater TT levels were associated with higher PA in subjects aged 40–80 years old. However, PA was assessed in the year prior to the survey, susceptible to recall bias. Evidence suggests that the increase in circulating testosterone levels only occurs within a short period of time from the onset of exercise and returns to baseline thereafter [18]. Moreover, the acute exercise-induced boost in TT has been studied [18].
a smaller magnitude of increase and relatively shorter time benefit [19].

While self-report is the most cost-effective and simple method to measure PA [11, 20] and can provide estimates of the type, duration, and exercise intensity in population-based studies; the differing questionnaires adopted and activity definitions often make it difficult to compare studies. For example, a cross-sectional analysis on 696 men from the European Prospective Investigation into Cancer and Nutrition study reported that high levels of vigorous exercise (i.e., 3 or more hours/week) were associated with an 11% higher testosterone concentration compared with those who reported no vigorous exercise [21]. However, no association was observed between total recreational exercise-time (<7.5, 7.5–14, or >14 h per week) and serum TT levels. In contrast, two studies examined the NHANES dataset with regard of sex steroid hormone levels and PA [10, 22]. The authors analyzed that NHANES cycles analyzed were the 1988–1991, 1991–1994, and 1999–2004 and reported that men in the highest category of frequency of PA had higher concentrations of TT consistent with the current report. Of note, Shiels et al. [22] found that those participants who had the highest PA per week had higher mean levels of TT though participating in vigorous exercise was not associated with higher TT levels. In contrast, Steeves et al. [10] noted an association between PA and TT only in those expending the highest level of energy and who were non-obese.

The etiology is uncertain, but some investigators have hypothesized mechanisms of action involving increasing...
caloric expenditure [23, 24]. For example, in vitro and in vivo evidence suggests a possible role for both the HPA axis as well as direct effect of exercise on the regulation of body mass composition. The effect of physical exercise in a rabbit model with metabolic syndrome-associated hypogonadotropic hypogonadism showed a down regulation of the majority of steroidogenic enzymes leading to T synthesis. Interestingly, the increase in genes related to inflammation, estrogen signaling, and glucose metabolism observed in metabolic syndrome were significantly reduced after the rabbits were exercise-trained to run on a treadmill for a 12-week period. In this model, Corona et al. [24] demonstrated how the expression of Kiss 1 gene and its receptor (Kiss1R) (neurotransmitters regulating GnRH secretion) functions, decreased orexigenic and GnRH-inhibiting factors (dopamine and its receptors OPRD1 and OPRK1), as well as increased anorexigenic ones (proopiomelanocortin) were significantly restored in the group of exercise-trained cabies.

Furthermore, studies from human professional sports have historically shown how physical effort directly damage muscle fibers leading to a subsequent increase in concentration of anabolic hormones such as insulin-growth factor-1 (IGF-I) or growth hormone (GH) [25]. Moreover, physical expenditure has been found to significantly change the Cortisol/T ratios that can impact on the secretion of GH and IGF-I from liver and the Cortisol/fT ratio that can impact on the secretion of GH 

Our present analysis is the first study assessing PA volume using objective measures of PA. We found that a higher physical expenditure quantified by the daily step count (or pax intensity) taken by each individual was associated with a lower odds of hypogonadal ranges total, free, and bioavailable T levels. While there were differences in baseline BMI and age among men with and without hypogonadism, the current work supports an association between daily steps, serum testosterone levels, and the risk of hypogonadism.

**Conclusion**

Our present analysis is the first study assessing PA volume using objective measures of PA. We found that a higher physical expenditure quantified by the daily step count (or pax intensity) taken by each individual was associated with a lower odds of hypogonadal ranges total, free, and bioavailable T levels. While there were differences in baseline BMI and age among men with and without hypogonadism, the current work supports an association between daily steps, serum testosterone levels, and the risk of hypogonadism.

**Funding** Open Access funding provided by Università degli Studi di Roma La Sapienza.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted
References

1. D.M. Kelly, T.H. Jones, Testosterone: a metabolic hormone in health and disease. J. Endocrinol. 217(3), R25–R45 (2013). https://doi.org/10.1530/JOE-12-0455

2. A. Salonia, G. Rastrelli, G. Hackett et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 5(1), 38 (2019). https://doi.org/10.1038/s41572-019-0087-y

3. F.C. Wu, A. Tajer, S.R. Pye et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93(7), 2737–2745 (2008). https://doi.org/10.1210/jc.2007-1426

4. D. Kapoor, H. Aldred, S. Clark, K.S. Channer, T.H. Jones, Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30(4), 911–917 (2007). https://doi.org/10.2337/dc06-0457

5. E.L. Ding, Y. Song, V.S. Malik, S. Liu, Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295(11), 1288–1299 (2006). https://doi.org/10.1001/jama.295.11.1288

6. C. Wang, E. Nieschlag, R.S. Swerdloff et al. EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 12(1), 5–12 (2009). https://doi.org/10.1080/1368530802389628

7. R.E. Rhodes, I. Janssen, S.S.D. Bredin, D.E.R. Warburton, A. Bauman, Physical activity: health impact, prevalence, correlates and interventions. Psychol Health 32(8), 942–975 (2017)

8. L. Thorsen, K.S. Courneya, C. Stevinson, S.D. Fossa, A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer 16(9), 987–997 (2008)

9. M.S. Shiel, S. Rohrmann, A. Menke et al. Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control 20(6), 877–886 (2009). https://doi.org/10.1007/s10552-009-9318-y

10. J.A. Stevens, E.C. Fitzgubh, G. Bradwin, K.A. McGlynn, E.A. Platz, C.E. Joshu, Cross-sectional association between physical activity and serum testosterone levels in US men: results from NHANES 1999–2004. Andrology 4(3), 465–472 (2016). https://doi.org/10.1111/andr.12169

11. R.K. Dishman, A.W. Richard, A.S. Dale, Measurement of physical activity. Quest 53(3), 295–309 (2001). https://doi.org/10.1080/00336297.2001.10491746

12. P.C. Hallal, F.F. Reichert, V.L. Clark et al. Energy expenditure compared to physical activity measured by accelerometer and self-report in adolescents: a validation study. PloS ONE 8(11), e77036 (2013). https://doi.org/10.1371/journal.pone.0077036

13. R.P. Troiano, D. Berrigan, K.W. Dodd, L.C. Mäse, T. Tilet, M. McDowell, Physical activity in the United States measured by accelerometer. Med. Sci. Sports Exerc. 40(1), 181–188 (2008). https://doi.org/10.1249/mss.0b013e31815a51b3

14. Vermeulen et al. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84(10), 3666–3672 (1999)

15. B. Liu, M. Yu, B.I. Graubard, R.P. Troiano, N. Schenker. Multiple imputation of completely missing repeated measures data within person from a complex sample: application to accelerometer data in the National Health and Nutrition Examination Survey. Stat. Med. 35(28), 5170–5188 (2016). https://doi.org/10.1002/sim.7049

16. P.F. Saint-Maurice, R.P. Troiano, D.R. Bassett Jr et al. Association of daily step count and step intensity with mortality among US adults. JAMA 323(12), 1151–1160 (2020). https://doi.org/10.1001/jama.2020.1382

17. M. Muller, I. den Tonkelaar, J.H. Thijszen, D.E. Grobbée, Y.T. van der Schouw, Endogenous sex hormones in men aged 40–80 years. Eur. J. Endocrinol. 149(6), 583–589 (2003). https://doi.org/10.1530/je.1.1490583

18. R.S. Swerdloff, C. Wang, Androgens and aging in men. Exp. Gerontol. 28(4-5), 435–446 (1993)

19. J.M. Zmuda, P.D. Thompson, S.J. Winters, Exercise increases serum testosterone and sex hormone-binding globulin levels in older men. Metabolism 45(8), 935–939 (1996). https://doi.org/10.1016/0026-0495(96)90258-9

20. J.M. Warren, U. Ekelund, H. Besson, A. Mezzani, N. Geladas, L. Vanhees, Assessment of physical activity—a review of methodologies with reference to epidemiological research: a report of the exercise physiology section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur. J. Cardiovasc. Prev. Rehabil. 17(2), 127–139 (2010). https://doi.org/10.1097/HJR.0b013e32833ed875

21. N.E. Allen, P.N. Appleby, G.K. Davey, T.J. Key, Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 13(4), 353–363 (2002). https://doi.org/10.1023/a:1015238102830

22. M.S. Shiel, S. Rohrmann, A. Menke et al. Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control 20(6), 877–886 (2009). https://doi.org/10.1007/s10552-009-9318-y

23. G. Corona, G. Rastrelli, M. Monami et al. Body weight loss reverses obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur. J. Endocrinol. 168(6), 829–843 (2013). https://doi.org/10.1530/JOE-12-0955

24. G. Corona, G. Rastrelli, A. Morelli et al. Treatment of functional hypogonadism besides pharmacological substitution. World J. Mens Health 38(3), 256–270 (2020). https://doi.org/10.5534/w jmh.190061

25. M. Barbara, K. Anna, Z.L. Agnieszka, The impact of professional sports activity on GH-IGF-I axis in relation to testosterone level. Am. J. Mens Health 14(1) (2020). https://doi.org/10.1177/1559828919883519

26. F. Del Giudice, G.M. Busetto, E. De Berardinis et al. A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. Asian J. Androl. 22(4), 360–367 (2020). https://doi.org/10.4103/aja.aja_101_19

27. S. Bhasin, T.W. Storer, A.B. Singh, L. Woodhouse, R. Singh, J. Artaza et al. Testosterone effects on the skeletal muscle. Testoster- one: Action, Deficiency, Substitution. (Cambridge University Press, Cambridge, UK, 2004), p. 255–282

28. B.D. Gonzalez, H.S. Jim, B.J. Small, S.K. Sutton, M.N. Fishman, B. Zachariah et al. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support. Care Cancer 24(5), 2201–2207 (2016)

29. L.V. Magnussen, L.G. Hvid, A.P. Hermann, D.M. Hougaard, B. Gram, P. Caserotti, M.S. Andersen, Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes—a randomized controlled trial. Andrology 5(5), 946–953 (2017). https://doi.org/10.1111/andr.12396